TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
ZYME

Zymeworks Inc.

Healthcare · Biotechnology

26.80$ -2.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Zymeworks Inc. (ZYME) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 397 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ZYME
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
98 94 80 115 100 132 114 211 194 244 238 415 400 368 637 607 572 538 490 472 420 389 430 369 300 649 601 602 556 581 554 516 487 463 426 408 397 347 478 397
56 46 33 70 54 92 74 172 154 204 190 366 345 312 505 471 487 455 433 393 337 288 324 263 191 545 426 420 375 413 394 383 344 300 306 296 292 233 386 298
28 16 10 26 12 36 31 55 28 42 43 284 251 128 189 220 244 242 280 257 253 202 276 199 96 401 182 142 94 158 115 71 122 66 76 98 65 41 244 179
52 40 27 62 49 88 70 166 150 200 180 356 335 299 488 437 472 426 411 360 308 253 301 242 166 492 341 340 295 374 345 330 297 226 265 281 252 229 365 271
2.7 4.3 2.4 3.1 2.0 2.3 2.0 2.2 1.3 1.4 1.0 2.8 3.4 2.2 8.7 15 3.7 15 4.6 9.2 4.9 16 4.2 4.2 6.7 33 67 49 67 19 31 32 24 56 25 2.6 29 4.6 4.7 5.9
– 0.0 – – 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 0.0 0.0 – – 0.0 – 0.0 – – – 0.0 – – – -72 0.0 – 0.0 0.0 – – – – – – – – –
– 6.7 7.7 7.4 7.5 7.2 6.9 6.8 6.4 6.5 14 16 16 17 17 18 13 12 12 39 19 23 26 26 49 48 46 43 39 – – – – – – – – – – –
12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12,016 12 12
0.1 21 19 19 19 19 19 19 21 20 19 18 25 24 24 25 24 23 22 21 20 21 22 24 27 26 26 25 26 25 25 7.5 6.6 4.6 3.4 2.0 1.4 1,350 1.2 1.0
20 85 89 18 17 16 19 25 25 64 68 81 91 123 114 116 139 128 113 150 141 140 148 147 121 156 127 153 132 116 116 109 120 124 101 74 77 78 315 317
11 17 21 13 12 15 18 24 24 30 28 40 51 83 73 73 97 86 70 83 75 72 80 80 58 96 67 94 73 56 57 55 84 88 65 39 42 42 36 47
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 1.7 0.9 1.3 1.8 1.9 1.9 2.7 3.0 1.6 1.3 1.3 1.1 2.7 4.6 3.3 3.4 3.6 3.8 4.3 4.2 2.8 2.9 2.7 3.3 3.6 3.4 3.5 3.3 3.3
2.6 3.0 2.1 2.0 2.0 1.7 1.0 5.6 1.2 2.6 1.4 4.1 7.2 5.3 12 4.7 3.1 6.2 4.9 4.7 5.0 5.2 14 5.9 0.3 7.9 6.4 15 11 6.2 2.5 1.7 3.4 3.9 5.2 0.0 1.3 4.4 30 27
– 4.4 4.5 0.0 0.1 0.1 0.1 0.0 0.0 – 6.4 – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
78 9.0 -9.0 97 83 116 95 186 170 180 170 334 310 246 522 491 432 410 377 321 279 249 282 222 180 493 474 449 424 465 438 406 367 339 325 335 320 269 164 80
-87 -98 -114 -125 -141 -109 -130 -136 -155 -145 -159 -188 -218 -291 -322 -361 -433 -471 -516 -583 -644 -683 -756 -820 -868 -559 -583 -634 -663 -677 -709 -747 -798 -830 -853 -851 -886 -953 -1,074 -1,171
20 20 20 21 25 25 25 27 32 32 32 33 43 44 49 51 51 51 51 51 52 52 61 66 66 67 67 67 71 71 76 76 76 76 75 77 76 75 75 73

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?